The U.S. medical establishment has been exposed operating a cynical cover-up of the dangers to women’s health from abortion pills. The trick is as simple as it is shockingly dishonest: Record abortion pill injuries as the result of spontaneous miscarriages. The result? Official statistics which understate the risk of taking the baby-killing drugs by a staggering 22 times.
This wicked deception has been exposed by a study from the Ethics and Public Policy Center (EPPC), released on April 28, 2025. This brought to light the deeply troubling reality of the abortion pill mifepristone, revealing a hidden crisis that has been obscured for far too long. This groundbreaking research, analyzing insurance claims data from 865,727 mifepristone abortions between 2017 and 2023, exposes a rate of serious complications that is alarmingly higher than what the Food and Drug Administration (FDA) has admitted.
Meanwhile, the pro-life Charlotte Lozier Institute (CLI) revealed that studies of Medicaid claims data for almost 29,000 post-abortion ER visits found that visits after the use of abortion drugs were 79% more likely to be “miscoded as miscarriages compared with surgical abortions.” Almost 84% of such cases were wrongly recorded from 2016 to 2021.
The findings not only challenge the narrative that mifepristone is a safe and effective option but also raise profound ethical concerns about how these complications are misrepresented, disguised as miscarriages, to downplay the risks to women.
A convenient overlap in diagnostic coding—where abortion-related complications are recorded similarly to miscarriages—obscures the drug’s risks. This practice, embedded in medical coding systems like ICD/CPT used across hospitals and insurance databases, includes those managed by the Centers for Medicare and Medicaid Services.
The Food and Drug Administration, which regulates mifepristone, has not addressed this coding issue directly in available data. Its reliance on clinical trial data rather than real-world evidence like the EPPC’s insurance claims analysis (covering 865,727 cases from 2017–2023) shows how the agency prioritizes the interests of the abortion industry over the safety and health of women.
Other parts of the medical-industrial complex are also implicated in the deceit. The American College of Obstetricians and Gynecologists (ACOG), which promotes the use of mifepristone, helped draw up the clinical guidelines which have permitted the deliberately confusing coding practices.
The EPPC study reveals that 10.93 percent of women who take mifepristone, the first drug in the two-drug medication abortion process, experience severe complications within 45 days of their abortion. These complications include life-threatening conditions such as sepsis, infection, hemorrhaging, and other serious adverse events.
This figure is staggering when compared to the FDA’s claim, based on clinical trials, that less than 0.5 percent of women experience such outcomes. The discrepancy - a rate 22 times higher than what the FDA reports - exposes a systemic failure to accurately represent the real-world dangers of mifepristone.
Unlike drug companies’ controlled clinical trials, which often involve carefully selected participants and close medical supervision, the EPPC’s analysis draws from a vast, real-world dataset that reflects the experiences of diverse women across the United States. By analyzing insurance claims data, the EPPC researchers were able to use a dataset 28 times larger than the self-serving clinical trials.
This makes the study’s findings far more representative of the actual risks women face when taking mifepristone, particularly in settings where oversight may be minimal, such as through telemedicine prescriptions.
Spontaneous miscarriages, and abortions induced by mifepristone, often involve similar symptoms, such as bleeding or incomplete expulsion of pregnancy tissue, but conflating them masks the specific risks associated with the abortion pill. This deliberate confusion not only misleads women about the safety of the procedure but also undermines their ability to make informed decisions about their health.
By obscuring the dangers of mifepristone, the medical establishment and abortion advocates have prioritized ideology over women’s health. This deception is doubly tragic. Not only does mifepristone end the lives of countless unborn children, but it also places women at significant risk, and denies them the right to know the real dangers.
Women are told that medication abortion is a simple, safe process, yet the data reveals a far more dangerous reality. The emotional and physical consequences of these complications include sepsis that can lead to organ failure, hemorrhaging that requires transfusions, and infections that threaten fertility.
These revelations have, however, produced grounds for hope that the situation will improve. Speaking during a Senate hearing on 14 May, 2025, Health and Human Services Secretary Robert F. Kennedy Jr. announced that he has directed FDA Commissioner Marty Makary to conduct a “complete review” of mifepristone’s safety, citing the EPPC study’s alarming findings.
Kennedy described the data as “alarming” and stated that, at the very least, the FDA should update the drug’s label to reflect the higher complication rate. This call for a review is a significant step toward acknowledging the risks that have been downplayed for years. Kennedy’s willingness to challenge the FDA’s narrative, despite his historically pro-abortion stance, suggests a commitment to prioritizing women’s health over political pressures.
Morality and demographic reality actually demand at least a massive curtailing of America’s abortion holocaust. But such major changes often come about in small incremental steps. The EPPC’s study highlighting the real dangers of the abortion pill is one such piece of progress. It’s the ideal subject for a short letter to your local paper; can you spare a few minutes to advance the pro-life cause?
